Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1396-1399

  Park, Seung Ha ^a   Kim, Chang Hoon ^b   Kim, Dong Joon ^c   Suk, Ki Tae ^c   Park, Jong Ha ^a   Cheong, Jae Youn ^d   Cho, Sung Won ^d   Hwang, Seong Gyu ^e   Lee, Youn Jae ^f   Cho, Mong ^g   Yang, Jin Mo ^h   Park, Ha Young ^a   Kim, Young Bae ^d  

^a Inje University College of Medicine   (South Korea)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c Chuncheon Sacred Heart Hospital   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e CHA University   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Pusan National University School of Medicine   (South Korea)

^h The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Biomarker; Chronic hepatitis C; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; GELATINASE A; HAPTOGLOBIN; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PLATELET RATIO INDEX; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; ALPHA-MACROGLOBULINS; APOLIPOPROTEIN A-I; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; COLLAGEN TYPE III; FEMALE; HAPTOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIVARIATE ANALYSIS; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 81555228605     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.08.1151     Document Type: Article

References (27)

1. Parkes J., Guha I.N., Roderick P., Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006, 44(3):462-474.
2. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51(10):1867-1873.
3. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357(9262):1069-1075.
4. McHutchison J.G., Blatt L.M., de Medina M., Craig J.R., Conrad A., Schiff E.R., et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000, 15(8):945-951.
5. Guechot J., Laudat A., Loria A., Serfaty L., Poupon R., Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996, 42(4):558-563.
6. Murawaki Y., Ikuta Y., Okamoto K., Koda M., Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001, 36(6):399-406.
7. Kim M.Y., Baik S.K., Jang Y.O., Suk K.T., Kim J.W., Kim H.S., et al. Serum hyaluronic acid level: correlation with quantitative measurement of hepatic fibrosis in a cirrhotic rat model. Korean J Hepatol 2008, 14(2):159-167.
8. Walsh K.M., Timms P., Campbell S., MacSween R.N., Morris A.J. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999, 44(3):624-630.
9. Boeker K.H., Haberkorn C.I., Michels D., Flemming P., Manns M.P., Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002, 316(1-2):71-81.
10. Larrousse M., Laguno M., Segarra M., De Lazzari E., Martinez E., Blanco J.L., et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007, 46(3):304-311.
11. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38(2):518-526.
12. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24(2):289-293.
13. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148(3):839-843.
14. Lackner C., Struber G., Liegl B., Leibl S., Ofner P., Bankuti C., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005, 41(6):1376-1382.
15. Idobe Y., Murawaki Y., Ikuta Y., Koda M., Kawasaki H. Post-prandial serum hyaluronan concentration in patients with chronic liver disease. Intern Med 1998, 37(7):568-575.
16. Pepe M.S., Janes H., Longton G., Leisenring W., Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159(9):882-890.
17. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127(6):1704-1713.
18. Patel K., Gordon S.C., Jacobson I., Hezode C., Oh E., Smith K.M., et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004, 41(6):935-942.
19. Moons K.G., van Es G.A., Michel B.C., Buller H.R., Habbema J.D., Grobbee D.E. Redundancy of single diagnostic test evaluation. Epidemiology 1999, 10(3):276-281.
20. Park S.H., Kim D.J., Cheong J.Y., Cho S.W., Hwang S.G., Lee Y.J., et al. Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: do new biomarkers improve the accuracy?. Clin Biochem 2010, 43(10-11):877-881.
21. Trinchet J.C., Hartmann D.J., Pateron D., Laarif M., Callard P., Ville G., et al. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J Hepatol 1991, 12(2):139-144.
22. Fukutomi T., Sakamoto S., Isobe H., Sakai H., Masumoto A., Nawata H. Clinical significance of the serum levels of the 7S domain of type IV collagen in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1992, 7(6):596-601.
23. Kim S.M., Sohn J.H., Kim T.Y., Roh Y.W., Eun C.S., Jeon Y.C., et al. Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease. Korean J Hepatol 2009, 15(4):454-463.
24. Misaki M., Shima T., Yano Y., Sumita Y., Kano U., Murata T., et al. Basement membrane-related and type III procollagen-related antigens in serum of patients with chronic viral liver disease. Clin Chem 1990, 36(3):522-524.
25. Nojgaard C., Johansen J.S., Christensen E., Skovgaard L.T., Price P.A., Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003, 39(2):179-186.
26. Ikura Y., Morimoto H., Ogami M., Jomura H., Ikeoka N., Sakurai M. Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J Gastroenterol 1997, 32(4):496-501.
27. Shiraishi T., Morimoto S., Koh E., Fukuo K., Ogihara T. Increased release of platelet-derived growth factor from platelets in chronic liver disease. Eur J Clin Chem Clin Biochem 1994, 32(1):5-9.